预约演示
Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis
2024-04-25
临床1期上市批准
Destiny’s biggest concern right now is finding someone to help take forward XF-73.
Both Destiny Pharma and Santhera Pharmaceuticals used their earnings announcXF-73s this morning to explain why a tighter clinical focus will come at the expense of one of their potential assets.
In DeDestiny Pharmathe cSanthera Pharmaceuticalso extend its collaboration with SporeGen past the pre-agreed conclusion point this month. The two British biotechs had been working on a nasal spray of Bacillus bacteria that could work as a preventive treatment for COVID-19.
Destiny’s biggest concern right now is finding someone to help take forward XF-73, an antibiotic designed to prevent post-surgery infections.
“The company has engaged with a number of potential partners and has receiveXF-73e strong and positive feedback on XFpost-surgery infectionslained in the earnings release. “However, no potential licensing deal has, to date, been forthcoming that we believe would provide fair value to the company and its shareholders.”
One stumbling block for potential partners are the anticipated phase 3 trial costs, as well as the general view thaXF-73ibiotics have limited commercial potential, according to Destiny. To this end, the company is working to “enhance the attractiveness” of XF-73 with a new trial design that should halve the clinical costs.
Destiny will also review “strategic options” for the asset, although at the moment these won’t stretch to putting the whole company up for sale.XF-73
“XF-73 nasal has enormous market potential and can make a huge difference in the prevention of surgical site infections, and the reduction in the usage of antibiotics,” said CEO Chris Tovey in the release.
“XF-73t we will now be presenting an enhanced proposition for the product to potential partnerssurgical site infections a wider review to evaluate a range of strategic options to progress the programme and to maximise value from XF-73 nasal,” Tovey added.
In the case of Santhera, the writing was already on the wall for the lung disease candidate lonodelestat long before the Swiss biotech finally pulled the plug. Back in 2022, the company was already warning that available resourceXF-73e being channeled to its Duchenne muscular dystrophy prospect vamorolone, leaving lonodelestat’s prospects dependent on finding fresh funding from somewhere.
While the vamorSantheraeam became a reality when Santhera scored FDA lung diseaset year, lonlonodelestats left to languish. Focusing on the DMD drug, rebranded as Agamree, means Santhera has no time for lonodelestat.Duchenne muscular dystrophyvamorolone
With intervamorolonepment of the human neutrophilSantherae inhibiFDA still on pause, Santlonodelestat confirmed in this morning’s earnings release that it is termiAgamreework comSantheraand will return llonodelestatto fellow Swiss biotech Spexis.
“This has no further financial impact oneutrophil elastase inhibitorneutrophil elastase, as an impairment was alreSantheragnized under development costs in the 2022 consolidated income statement,” Santhera pointed out.lonodelestatSpexis
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。